scholarly journals The Effect of 12 Weeks of Interval and Continuous Training on Serum Levels of Interleukin-17 and Interleukin-10 in Postmenopausal Breast Cancer Survivors: A Clinical Trial

2021 ◽  
Vol 14 (2) ◽  
pp. 4-15
Author(s):  
Parisa Pournemati ◽  
◽  
Babak Hooshmand Moghadam ◽  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Interleukin 17 ◽  
Continuous Training

scholarly journals Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors

2012 ◽  
Vol 21 (4) ◽  
pp. 456-462 ◽  
Author(s):  
Claire F. Friedman ◽  
Angela DeMichele ◽  
H. Irene Su ◽  
Rui Feng ◽  
Shiv Kapoor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Survivors ◽  
Vitamin D Deficiency ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12501-e12501
Author(s):  
Christina Marie Dieli-Conwright ◽  
Maura Harrigan ◽  
Brenda Cartmel ◽  
Anees B. Chagpar ◽  
Yalai Bai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Weight Loss ◽  
Body Composition ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Breast Tissue ◽  
Serum Levels ◽  
Serum Biomarkers ◽  
Weight Loss Intervention ◽  
Tissue Biomarkers

e12501 Background: Weight loss interventions are effective approaches to reduce body weight and alter serum biomarkers in breast cancer survivors, however the impact on breast tissue biomarkers is unknown. The Lifestyle, Exercise and Nutrition (LEAN) study was a randomized trial designed to test the effect of a weight loss intervention on body composition and breast tissue and serum biomarkers. Methods: Fifity-one women with a BMI ³ 25.0 kg/m2 diagnosed with breast cancer, who had completed chemotherapy and/or radiation therapy were randomized to weight loss intervention or usual care. Breast tissue biopsies from the unaffected breast, fasting serum samples, and body composition were measured at baseline and 6-months. Ki67, insulin receptor (IR), CD68 and CD163 were measured by Automated Quantitative Analysis (AQUA) method. Mean baseline to 6-month changes were compared using ANCOVA adjusting for baseline values. Results: Pre- and post-intervention biopsies were conducted in 49 and 42 women respectively, with both pre- and post- epithelial tissue available from 25 women; epithelial tissue was unavailable in the remaining 66 women. Women were 56.8 ± 8.9 years old, diagnosed 3.3 + 3.8 years prior, primarily Stage I breast cancer (54%), with a BMI of 32.8 ± 6.0 kg/m2. At baseline, breast tissue levels of IR were inversely associated with both percent body fat (r = -0.47, p = .03) and serum insulin levels (r = -0.45, p = .04); serum insulin levels were inversely associated with CD68 (r = -0.47, p = .03). Significant between-group biomarker changes are presented in Table 1. At month 6, loss in percent body fat was associated with increased IR (r = -0.42, p = .05). Increased CD68 breast tissue expression was associated with reductions in serum levels of CRP (r = -0.49, p=0.02). There was no significant effect of the intervention on IR expression or Ki67 (p>0.10). Conclusions: Breast tissue biopsies are feasible to collect in a clinical research setting among breast cancer survivors. A 6-month weight loss intervention led to decreased levels of CD163 in breast tissue and serum levels of leptin, and increased serum levels of adiponectin among breast cancer survivors. At baseline and month 6, changes in breast tissue biomarkers were favorably associated with serum biomarkers and body composition. Future confirmation is required to confirm the added benefit of tissue biomarkers beyond serum as an endpoint for lifestyle interventions among breast cancer survivors. Clinical trial information: NCT02110641. [Table: see text]

scholarly journals Telehealth system (e-CUIDATE) to improve quality of life in breast cancer survivors: rationale and study protocol for a randomized clinical trial

Trials ◽  
2013 ◽  
Vol 14 (1) ◽  
pp. 187 ◽  
Author(s):  
Noelia Galiano-Castillo ◽  
Angelica Ariza-García ◽  
Irene Cantarero-Villanueva ◽  
Carolina Fernández-Lao ◽  
Lourdes Díaz-Rodríguez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Cancer Survivors ◽  
Randomized Clinical Trial ◽  
Study Protocol ◽  
Breast Cancer Survivors ◽  
Improve Quality

Testing an Intervention for Preventing Osteoporosis in Postmenopausal Breast Cancer Survivors

2003 ◽  
Vol 35 (4) ◽  
pp. 333-338 ◽  
Author(s):  
Nancy L. Waltman ◽  
Janice J. Twiss ◽  
Carol D. Ott ◽  
Gloria Jean Gross ◽  
Ada M. Lindsey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer

scholarly journals Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator

2012 ◽  
Vol 8 (3) ◽  
pp. 144-148 ◽  
Author(s):  
Shannon Wills ◽  
Anita Ravipati ◽  
Padmaja Venuturumilli ◽  
Cynthia Kresge ◽  
Elizabeth Folkerd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Serum Estradiol ◽  
Estradiol Treatment ◽  
Receptor Modulator ◽  
Estradiol Levels

The authors conclude that intravaginal estradiol treatment, regardless of type, results in elevated circulating E2 levels in this population and should be used with caution.

Sign in / Sign up

Export Citation Format

Share Document